Antony Hsieh

Antony Hsieh currently serves as Clinical Development Lead for Immunology and Inflammation at Dragonfly Therapeutics, Inc. since August 2024 and as a Gastroenterologist for the U.S. Department of Veterans Affairs since 2023. Prior roles include Vice President of Clinical Strategy at Tome Biosciences from July 2022 to August 2024, Medical Director of Clinical Development at Blueprint Medicines from December 2020 to July 2022, and Medical Director of Clinical Development at GSK for the latter half of 2020. Antony Hsieh also held academic positions as a Research Fellow in Cancer Biology at the University of Pennsylvania School of Medicine and as a Gastroenterology Fellow at Penn Medicine from 2017 to 2020. An Internal Medicine Resident at Northwestern Memorial Hospital between 2014 and 2017, Antony Hsieh further contributed as a Research Fellow in Gastroenterology & Hepatology during that time. Earlier research experience includes a fellowship in Molecular Biology with the Howard Hughes Medical Institute. Antony Hsieh earned a Doctor of Medicine degree from The Johns Hopkins University School of Medicine and a Bachelor's degree in Molecular Biology from the University of Arizona.